EUROSTARS supported ASTORIA study using Pilloxa’s digital medication adherence solution in cardiovascular disease patients begins
Stockholm, Sweden, March 9, 2022: Digital health company Pilloxa today announced that the First Patient First Visit milestone has been reached in the ASTORIA* study – a single-armed and multicenter observational clinical trial in which their digital patient-centric adherence solution is being tested in cardiovascular disease patients, namely newly diagnosed patients with atrial fibrillation. Professor Dan Atar from the University of Oslo is the sponsor of the study, financial support is provided by an EU-grant from the EUROSTARS program and Bayer.The primary objective of the study is to